PT  - JOURNAL ARTICLE
AU  - Han, Jinsheng
AU  - Gao, Fei
AU  - Geng, Songsong
AU  - Ye, Xueshuai
AU  - Wang, Tie
AU  - Du, Pingping
AU  - Cai, Ziqi
AU  - Fu, Zexian
AU  - Zhao, Zhilong
AU  - Shi, Long
AU  - Li, Qingxia
AU  - Cai, Jianhui
TI  - Minicircle DNA-Engineered CAR T Cells Suppressed Tumor Growth in Mice
AID  - 10.1158/1535-7163.MCT-19-0204
DP  - 2020 Jan 01
TA  - Molecular Cancer Therapeutics
PG  - 178--186
VI  - 19
IP  - 1
4099  - http://mct.aacrjournals.org/content/19/1/178.short
4100  - http://mct.aacrjournals.org/content/19/1/178.full
SO  - Mol Cancer Ther2020 Jan 01; 19
AB  - Viral-based chimeric antigen receptor-engineered T (CAR T)–cell manufacturing has potential safety risks and relatively high costs. The nonviral minicircle DNA (mcDNA) is safer for patients, cheaper to produce, and may be a more suitable technique to generate CAR T cells. In this study, we produced mcDNA-based CAR T cells specifically targeting prostate stem cell antigen (PSCA; mcDNA-PSCA-CAR T cells). Our results showed that mcDNA-PSCA-CAR T cells persisted in mouse peripheral blood as long as 28 days and demonstrated more CAR T-cell infiltration, higher cytokine secretion levels, and better antitumor effects. Together, our results suggest that mcDNA-CAR can be a safe and cost-effective platform to produce CAR T cells.